Protalix BioTherapeutics (PLX) stock rises as an EU panel recommends approval of a new dosing regimen for the company's Fabry disease drug Elfabrio. Read more here.
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be ...
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be ...
Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is ...
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical ...
A new study reveals how bacteria in the gut can help determine whether the amino acid asparagine from the diet will feed tumor growth or activate immune cells against the cancer, according to ...
Bare Skin and Beauty, an established skin care clinic with locations in Hillarys and Ellenbrook, is addressing the increasing ...
SCAC, while rare, is primarily driven by the human papillomavirus (HPV) and accounts for about 85% of all anal cancers. There ...
New research suggests THC’s cognitive drawbacks may be mitigated when combined with a targeted anti-inflammatory drug. Cannabis research has highlighted a scientific paradox. Its best-known ...
Dermatology is entering a "biological revolution," with engineered tissues and bio-machines offering new therapeutic ...
In a recent study, a team of scientists discovered that a treatment using different medications was found to be effective to ...
Asianet Newsable on MSN
PLX shares jump 13% on EMA committee’s turnaround on new dosing regimen for Fabry disease therapy
The Committee for Medicinal Products for Human Use recommended approval of the 2mg/kg every-4-weeks dosing regimen in Fabry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results